Abstract: Nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof in which a therapeutically effective amount of the nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof is administered to the subject.

Abstract: Nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of SAPHO syndrome in a subject in need thereof. The subject suffers from one first symptom which is an osteoarticular symptom of SAPHO syndrome selected from synovitis, osteitis, primitive inflammatory osteitis, hyperostosis, axial spondyloarthritis, arthritis, enthesitis, and diffuse idiopathic skeletal hyperostosis (DISH)-like non-marginal enthesophytes, and at least one second symptom of SAPHO syndrome different from the first system.

Abstract: The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.

Abstract: The invention concerns nicotinamide mononucleotide, a pharmaceutically acceptable derivative, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of rheumatoid arthritis, as well as compositions comprising it.

Abstract: The disclosure relates to compounds of formula (I) and/or of formula (Ia) for the prevention and/or treatment of depression and/or anxiety related to a Parkinsonism such as an alpha-synucleinopathy as well as compositions and kit of parts including the same.

Abstract: The present disclosure relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present disclosure further relates to pharmaceutical compositions including compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.

Abstract: The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of an antineoplastic-induced toxicity. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of an antineoplastic-induced toxicity.

Abstract: The invention relates to nicotinamide mononucleotide, a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, for use in preventing and/or treating joint pain induced by physical activity, and compositions comprising same.

Abstract: The invention pertains to a cosmetic composition comprising NMN, a precursor thereof, a derivative thereof, against skin ageing.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; in which X, R1, R2, R3, R4, R5, R6, R7, R8, Y, and are as described in the claims, for the use thereof in the treatment of bacterial infections including those caused by caused by at least one bacterium of the genus selected from aerobic Gram-positive bacteria; Gram-negative enterobacteria; Gram-negative bacilli; Gram-negative anaerobic bacteria; Gram-positive anaerobic bacteria; mycobacteria and pathogens involved in sexually transmitted infections.

Abstract: Nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, are described for use thereof in the prevention and/or treatment of a back pain such as a lumbalgia (low back pain), a dorsalgia (severe back pain), or a cervicalgia (neck pain), preferably a chronic lumbalgia; as well as compositions that include the same.

Abstract: Nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, are described for use thereof in the prevention and/or treatment of a muscle, ligament, tendon or their combination, induced by physical activity; as well as compositions that include the same.

Abstract: Nicotinamide mononucleotide derivatives of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections, and pharmaceutical compositions including compounds of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections are disclosed.

Abstract: The invention pertains to nicotinamide mononucleotide, a pharmaceutically acceptable derivative thereof, a pharmaceutically acceptable precursor thereof, or a pharmaceutically acceptable salt thereof, for use thereof in decreasing immunosenescence and/or for improving immune response to vaccination, and to compositions comprising the same.

Abstract: A method for treating arrythmia in subject in need thereof, which includes administering to the subject a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; in which X, R1, R2, R3, R4, R5, R6, R7, R8, Y, and are as described in the claims.

Abstract: A compound of formula I or pharmaceutically acceptable salts and/or solvates thereof: Also, compositions including at least one compound of formula I, such a pharmaceutical composition, a food composition, and a cosmetic composition. Further, a method for preparing compounds of formula I and their use as therapeutic compounds for use in the treatment of pain, antineoplastic-induced cardiotoxicity or sickle cell disease.

Abstract: The invention relates to nicotinamide mononucleotide, a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, for use in preventing and/or treating joint pain induced by physical activity, and compositions comprising same.

Abstract: The invention concerns a compound of formula (I) and/or a compound of formula (Ia) for use in the prevention and/or treatment of ankylosing spondylitis, as well as compositions and combination preparations comprising them.

Abstract: The present disclosure relates to combinations of histamine H2 receptor antagonist and Nicotinamide mononucleotide derivatives of formula (I) or a compound of formula (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections, preferably coronavirus infections. The present disclosure further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.

Abstract: The present disclosure relates to Nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present disclosure further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and/or prevention of viral infections.